

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (cancelled).

Claim 22 (currently amended). A composition for treating ~~a skin disorder~~ melanoma,
comprising:

a pharmaceutically acceptable carrier; and

an active ingredient of inorganic ions comprising 1-40 parts rubidium and at least one other
ion selected from the group consisting of 10-80 parts potassium, 0.00001-20 parts zinc, and 0.01-10
parts calcium, wherein the active ingredient comprises 80% by weight of the composition;

wherein the composition has a pH of approximately 4-7.

Claim 23 (previously presented). The composition of Claim 22 wherein the
pharmaceutically acceptable carrier is selected from the group consisting of ointments, creams,
hydrogels, alginates, and kerosol.

Claim 24 (currently amended). A method for treating ~~a skin disorder~~ Kaposi's sarcoma
lesions comprising:

~~providing~~ applying a first therapeutic composition to the lesion, the first therapeutic composition comprising a pharmaceutically acceptable carrier and an active ingredient of inorganic ions comprising 1-40 parts rubidium and at least one other ion selected from the group consisting of potassium, zinc, and calcium, wherein the active ingredient comprises 50% by weight of the composition;~~wherein the composition has a pH of approximately 4-7;~~

monitoring the lesion to identify a size of the lesion; and

~~applying the~~ a second therapeutic composition to the skin lesion, the second therapeutic composition comprising a pharmaceutically acceptable carrier and an active ingredient of inorganic ions comprising 1-40 parts rubidium and at least one other ion selected from the group consisting of potassium, zinc, and calcium, wherein the active ingredient comprises 20% by weight of the composition.;

~~wherein the skin disorder is selected from the group consisting of psoriasis, impetigo, Kaposi sarcoma, acne, melanoma, lesions, and gangrene.~~

Claim 25 (cancelled).

Claim 26 (new). The method of Claim 24, wherein the size is approximately one inch in diameter.

Claim 27 (new). The method of Claim 24, wherein the first therapeutic composition comprises 10-80 parts potassium.

Claim 28 (new). The method of Claim 24, wherein the first therapeutic composition comprises 0.00001-20 parts zinc.

Claim 29 (new). The method of Claim 24, wherein the first therapeutic composition comprises 0.01-10 parts calcium.

Claim 30 (new). The method of Claim 24, wherein the second therapeutic composition comprises 10-80 parts potassium.

Claim 31 (new). The method of Claim 24, wherein the second therapeutic composition comprises 0.00001-20 parts zinc.

Claim 32 (new). The method of Claim 24, wherein the second therapeutic composition comprises 0.01-20 parts calcium.

Claim 33 (new). The method of Claim 24, wherein the pharmaceutically acceptable carrier of the first therapeutic composition comprises polyethylene glycol.

Claim 34 (new). The method of Claim 24, wherein the pharmaceutically acceptable carrier of the second therapeutic composition comprises polyethylene glycol.

Claim 35 (new). A method for treating melanoma comprising:

removing exudates from the melanoma;

applying a therapeutic composition to the melanoma, the therapeutic composition comprising a pharmaceutically acceptable carrier and an active ingredient of inorganic ions comprising 1-40 parts rubidium and at least one other ion selected from the group consisting of potassium, zinc, and calcium, wherein the active ingredient comprises 80% by weight of the composition; and

monitoring the size of the melanoma.

Claim 36 (new). The method of Claim 35, wherein applying the therapeutic composition comprises applying the therapeutic composition on a daily basis.

Claim 37 (new). The method of Claim 35, wherein applying the therapeutic composition comprises applying the therapeutic composition on a twice daily basis.

Claim 38 (new). The method of Claim 35, wherein the therapeutic composition comprises 10-80 parts potassium.

Claim 39 (new). The method of Claim 35, wherein the therapeutic composition comprises 0.00001-20 parts zinc.

Claim 40 (new). The method of Claim 35, wherein the therapeutic composition comprises 0.01-10 parts calcium.

Claim 41 (new). The method of Claim 35, wherein removing exudates from the melanoma comprises washing the melanoma with soap and water.

Claim 42 (new). The composition of Claim 22 wherein the pharmaceutically acceptable carrier comprises polyethylene glycol.